Unexplained Infertility
The enigma of unexplained infertility remains no less puzzling and presents the same pressing problems today as it has throughout recorded history. Both the Old and New Testaments contain dramatic accounts of barren women who solved their problem either by prayer, by fasting, or by resorting to some current nostrum. We are moved by the poignant story of infertile Rachel who, in deep anguish, cried out to her husband, Jacob, 'Give me children or else I die'. She bargained with prolific Leah to obtain the freshly gathered mandrakes from Reuben, Leah's son. The Book of Genesis then relates Rachel's triumphthe fruit of her womb was Joseph. It may well be that the calming action of mandrake root lessened her anxiety, permitting better hypothalamic-pituitary function (Greenblatt 1963) .
I can say gratefully that I have had more than a modicum of success in the management of women with unexplained infertility by utilizing the 'delay of menses test', which some colleagues charitably eponymize as the dreenblatt-Swyer test. The test was devised as a measurement of the efficacy of a given progestational agent. Such compounds have become available in increasing numbers during the past decade. Originally, I suggested that the test agent should be given to women with normal cycles whose basal temperature records readily conform to the norm. The drug was started six or seven days after ovulation and administered for a period of twenty days. The test was termed successful when menstruation was delayed beyond termination of medication (Greenblatt 1958) . Since many progestogens have inherent cestrogenic activity, Swyer & Little (1962) suggested that the test would be more uniform and meaningful if a standard dose of estrogen was added. Accordingly, either 100 pg of ethinyl cestradiol or mestranol was incorporated. The cestrogen, per se, even in five times that dosage, failed to delay the onset of menses. The smallest amount of a progestogen (given with the standard dose of cestrogen) which delayed the onset of menses was considered adequate to substitute for the regressing corpus luteum. We have thus been able to offer some index of the efficacy of a large variety of progestogens (Greenblatt 1966) . Some of the subjects studied were women with unexplained infertility. We were surprised that many conceived during the testing or within a month or two thereafter. I do not know if these unexpected results were due to a change in endocrine environment, or if the mere interest shown in the patient removed some of the cerebral influences that adversely affected subtle hypothalamic-pituitary mechanisms.
The Stein-Leventhal Syndrome There are many concepts concerning the nature of the Stein-Leventhal syndrome. Many fallacies have been perpetuatedone of these is that the thick ovarian capsule is a mechanical barrier to ovulation. Wedge resection was remedial, it was believed, by attenuating the capsule along the line of incision (Ingersoll & McDermott 1950 ). The following points refute such a concept:
(1) Spontaneous ovulation occasionally occurs after stress situations. In a woman who had not menstruated for over a year I saw at laparotomy a fresh corpus luteum in classically enlarged pale ovaries with thickened tunica. Histological examination of the ovarian wedges failed to reveal any evidence of past ovulations, i.e. corpora albicantes. Similar observations have been made in other instances (Greenblatt & Baldwin 1960) .
(2) Hemicastration was performed on 4 wOmen with typical Stein-Leventhal syndrome. Each of them ovulated regularly after the unilateral ovariectomy from the contralateral ovary despite the thickened capsule.
(3) Certain women with Stein-Leventhal syndrome have responded to low dosage corticosteroid therapy. In a few, ovulation occurred irregularly with cortisone but regularly after wedge resection (Greenblatt 1953) .
Section ofEndocrinology (4) Clomiphene readily induced ovulation in about 80% of the patients diagnosed as having the Stein-Leventhal syndrome. Multiple ovulation was found frequently at laparotomy following such therapy.
(5) Gonadotrophins obtained from human pituitaries or menopausal urine when followed by HCG readily stimulated ovulatory responses in women with this syndrome. It is apparent from the foregoing evidence that the thickened capsule is not an impediment to ovulation.
Another notion widely held is that the increased level of urinary 17-ketosteroids found in many cases of Stein-Leventhal syndrome were of adrenal origin. Hormonal assays after adrenal suppression and after gonadotrophin stimulation while the adrenals remain suppressed indicate -that in most instances the ovaries are the source of much of the androgens (Mahesh & Greenblatt 1962) .
Another concept that has been entertained is that the syndrome is due to hypergonadotrophinism. FSH has been indicted by Sommers & Wadman (1956) and persistently increased levels of LH found by McArthur et al. (1958) . In our own studies, total urinary gonadotrophins were within the normal limits. One patient was in hospital for one month and forty-eight hour urine specimens were collected for FSH and LH determinations (by courtesy of Dr A Parlow). There was no consistent elevation of either FSH or LH during the control period. About ten days after clomiphene therapy there was a sharp rise in FSH output, soon followed by a surge in LH. Ovulation occurred, after which both FSH and LH fell to pretreatment levels (Roy et al. 1963) .
It is my belief that the Stein-Leventhal syndrome is really an example of hyperovarianism. The ovaries, under continuous gonadotrophin stimulation and lacking the cyclic regulation, respond with a myriad of immature follicles and marked theca and stromal cell activity. Because of the absence of corpora lutea, steroidogenesis is predominantly from the theca and interstitium, resulting in excess production of androgen prccursors, particularly dehydroepiandrosterone and A4-androstenedione , Rice & Savard 1966 ). An ovarian enzymatic disorder has been postulated by Mahesh & Greenblatt (1962) . Their studies suggested an inadequacy of 3,-ol-dehydrogenase or a defect in the aromatizing systems. The enzymatic disorder, in all probability, is only relative. Once corpora lutea are formed with any degree of regularity, the ovulatory process may become temporarily or permanently normal. The abnormal steroidogerisis, however, according to Zander et al. (1962) , may not disappear.
Reduction in ovarian mass permits more gonadotrophins to become available per unit of ovarian tissue. Any regimen that changes the ratio of gonadotrophin to ovarian mass may provoke the ovulatory process, such as the addition of exogenous gonadotrophins (HMG and HCG) or the administration of clomiphene, which is thought to cause release of more gonadotrophins.
Clomiphene as an Ovulation-inducing Agent Clomiphene citrate, an analogue of the synthetic nonsteroidal cestrogen, chlorotrianisene (TACE), was shown to have marked ovulation-inducing propensities in the human but no progestational, androgenic or corticoid properties (Greenblatt 1961) . The agent has been shown to be mildly oestrogenic in immature rats but anti-estrogenic in mature or in cestrogen-treated castrated rats (Roy et al. 1964) .
When clomiphene was first studied in experimental animals, it was found to have antigonadotrophic, antizygotic and antifecundity faculties (Holtkamp 1960) . Ovulation and spermatogenesis could be suppressed in rats (Segal & Nelson 1961) . Conversely, in the human, gonadotrophinreleasing effects were demonstrated, and the agent was found useful in the treatment of oligomenorrhcea, dysfunctional uterine bleeding, the Stein-Leventhal syndrome, Chiari-Frommel syndrome, secondary amenorrhoea and in women with an inadequate luteal phase.
In our series ofsome 450 women treated because of ovulatory failure, ovulation was thought to have been induced in over 60 %. The dosage was from 25 to 200 mg for five to twenty days or longer. However, with the larger doses, ovarian cyst formation frequently occurred as did severe hot flushes. These complications were greatly reduced on doses of 25-50 mg for five to ten days, but efficacy was also lessened. In our series, over 100 conceptions have occurred, and 80 of these women have now been delivered; amongst the children were 7 sets of non-identical twins. The incidence of feetal anomalies was within the normal range. There was no instance of phocomelia. Not all patients treated wanted to become pregnant.
The drug has few side-effects. Multiple pregnancies of 3 or 4 siblings have been reported Occasional massive ovarian cysts have developed which required surgery, although in most cases re#ession of the cysts took place within six weeks after discontinuation of treatment. To us, this untoward reaction was a good omen, for it indicated responsiveness of the ovaries, though warning us that future dosage must be radically reduced. Hot flushes occur during therapy but subside with termination of medication. Concomitant cestrogen administration did not eradicate vasomotor disturbances. Mode of action: Most investigators believe that clomiphene induces ovulation by releasing endogenous gonadotrophins. It is thought that the gonadotrophin-releasing effect is due to the anti-aestrogenic properties. There are, however, several patients with Chiari-Frommel syndrome in whom the vaginal cytology was castrate in type, the endometrium atrophic and urinary gonadotrophins not measurable, and yet clomiphene is capable of stimulating ovulation (Greenblatt et al. 1967) . The release of gonadotrophins in such cases may be due to the direct action of clomiphene on the hypothalamico-pituitary axis.
To conclude, I need not describe the role of higher cerebral centres in the control of fertility and endocrine gland activity. In stress amenorrhoea the hypothalamus may fail to secrete FSH and/or LH releasing factors. In amenorrhoea with persistent lactation there may be an inadequate release of the prolactin-inhibiting factor. In pseudocyesis, strong cerebral impulses may stimulate excess of the LH-releasing factor.
We have come to realize the importance of emotional factors in modifying the release or inhibition of the neurohumours from the hypothalamus thus affecting pituitary activity and ovarian function.
